Tenet Healthcare (NYSE:THC) CEO Saumya Sutaria Sells 78,762 Shares

Tenet Healthcare Corporation (NYSE:THC) CEO Saumya Sutaria sold 78,762 shares of Tenet Healthcare stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $190.78, for a total transaction of $15,026,214.36. Following the sale, the chief executive officer directly owned 368,683 shares of the company’s stock, valued at $70,337,342.74. This trade represents a 17.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Tenet Healthcare Trading Down 0.4%

Shares of NYSE:THC opened at $192.60 on Friday. The firm has a fifty day moving average of $173.91 and a two-hundred day moving average of $155.04. The firm has a market capitalization of $17.02 billion, a P/E ratio of 12.33, a price-to-earnings-growth ratio of 0.83 and a beta of 1.55. Tenet Healthcare Corporation has a 12-month low of $109.82 and a 12-month high of $199.99. The company has a quick ratio of 1.63, a current ratio of 1.71 and a debt-to-equity ratio of 2.39.

Tenet Healthcare (NYSE:THC) last issued its earnings results on Tuesday, July 22nd. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $1.18. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.16 billion. Tenet Healthcare had a net margin of 7.17% and a return on equity of 24.69%. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter last year, the business posted $2.31 EPS. Tenet Healthcare has set its FY 2025 guidance at 15.550-16.210 EPS. On average, equities analysts expect that Tenet Healthcare Corporation will post 12.24 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on THC. Wall Street Zen upgraded shares of Tenet Healthcare from a “hold” rating to a “strong-buy” rating in a report on Saturday, July 26th. UBS Group raised their price target on shares of Tenet Healthcare from $230.00 to $238.00 and gave the company a “buy” rating in a report on Wednesday, July 23rd. Stephens upgraded shares of Tenet Healthcare to a “strong-buy” rating in a report on Monday, June 2nd. Wolfe Research downgraded shares of Tenet Healthcare from an “outperform” rating to a “peer perform” rating in a report on Monday, July 28th. Finally, Barclays cut their price target on shares of Tenet Healthcare from $215.00 to $208.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Tenet Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $195.50.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in Tenet Healthcare in the 1st quarter worth $26,000. Chung Wu Investment Group LLC acquired a new stake in Tenet Healthcare in the 2nd quarter worth $35,000. Canada Pension Plan Investment Board acquired a new stake in Tenet Healthcare in the 2nd quarter worth $35,000. Wayfinding Financial LLC acquired a new stake in Tenet Healthcare in the 1st quarter worth $28,000. Finally, SVB Wealth LLC acquired a new stake in Tenet Healthcare in the 1st quarter worth $30,000. Institutional investors own 95.44% of the company’s stock.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.